Abstract
Preliminary data from a phase 4 post-marketing safety trial of the arthritis drug tofacitinib have turned up worrying results for the Janus kinase (JAK) inhibitor, indicating an elevated risk of causing heart problems and cancer in some patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
